

Don't miss this important meeting,  
coming soon to your area ...

**Sunovion Representative**  
Kristine Hahn  
kristine.hahn@sunovion.com  
585-330-8932

# Bipolar Depression: Presentation, Diagnosis, and Treatment

## IN THE HISPANIC POPULATION

This promotional, non-CME program is intended only for healthcare professionals involved in the treatment of adult patients with bipolar disorder.

### GET AN UPDATE ON:

- Healthcare disparities among Hispanic patients with bipolar depression
- Key considerations in the diagnosis and management of this patient population
- Clinical trials data on an approved treatment option

#### Presented by:

Horacio A. Capote, MD  
Clinical Assistant Professor  
State University of New York  
at Buffalo School of Medicine  
Buffalo, NY  
Medical Director  
Division of Neuropsychiatry  
Dent Neurologic Institute  
Amherst, NY

Thursday, December 17, 2015

6:00 PM

Havana Cabana - Island Cafe & Rum Bar  
289 Alexander St  
Rochester, NY 14607  
585-232-1333

#### Meeting Code:

31272

Attendees will have the option to accept the Sunovion-provided food and beverage service, opt out of all food and beverage, or purchase their own food and beverage.

**Seating is limited, so register now.**

**Enter the provided meeting code at [www.sunovionmeetings.com](http://www.sunovionmeetings.com).**

Registration is preferred. There is no cost to attend this meeting. Please note: This program is subject to cancellation if fewer than 3 healthcare professionals are in attendance. For additional program information, call (866) 801-0824; reference the provided meeting code.

#### INDICATIONS AND USAGE

Latuda® (lurasidone HCl) is indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

#### IMPORTANT SAFETY INFORMATION FOR LATUDA

**Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.**

Please see additional Important Safety Information, including **Boxed Warning**, below and accompanying [full Prescribing Information](#).

 **Latuda®**  
(lurasidone HCl)

LATUDA, SUNOVION, and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2015 Sunovion Pharmaceuticals Inc. All rights reserved. LAT173-15 03/15

This promotional  
non-CME program is  
sponsored by  
 **SUNOVION**

## IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

**Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.**

## CONTRAINDICATIONS

LATUDA is contraindicated in the following:

- Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone.
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
- Strong CYP3A4 inducers (e.g., rifampin)

## WARNINGS AND PRECAUTIONS

**Cerebrovascular Adverse Reactions, Including Stroke:** In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

**Neuroleptic Malignant Syndrome (NMS):** NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

**Tardive Dyskinesia (TD):** TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

### Metabolic Changes

**Hyperglycemia and Diabetes Mellitus:** Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

**Dyslipidemia:** Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

**Weight Gain:** Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

**Hyperprolactinemia:** As with other drugs that antagonize dopamine D<sub>2</sub> receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

In the short-term, placebo-controlled monotherapy study, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was 3.1 ng/mL and was 1.5 ng/mL for males. The proportion of female patients with prolactin elevations  $\geq 5\times$  ULN was 0.6% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations  $\geq 5\times$  ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated male patients.

In the short-term, placebo-controlled adjunctive therapy with lithium or valproate study, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was 3.2 ng/mL and was 2.4 ng/mL for males. The proportion of female patients with prolactin elevations  $\geq 5\times$  ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations  $\geq 5\times$  ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated male patients.

**Leukopenia, Neutropenia, and Agranulocytosis:** Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

**Orthostatic Hypotension and Syncope:** LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension, in patients with known cardiovascular disease or history of cerebrovascular disease, and in patients who are antipsychotic-naïve.

**Seizures:** LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer's dementia).

**Potential for Cognitive and Motor Impairment:** Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

**Body Temperature Regulation:** Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

**Suicide:** The possibility of suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

## ADVERSE REACTIONS

Commonly observed adverse reactions ( $\geq 5\%$  incidence and at least twice the rate of placebo) for LATUDA were akathisia, extrapyramidal symptoms, and somnolence.

## INDICATIONS

LATUDA is indicated for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate in adults.

Before prescribing LATUDA, please read the accompanying [full Prescribing Information](#), including **Boxed Warning**.

---

Sunovion Pharmaceuticals Inc. is committed to the principles in the PhRMA Code on Interactions with Healthcare Professionals. This code helps to ensure that the highest professional and ethical standards are being met in the pharmaceutical industry. As part of our commitment to the PhRMA code, please note that attendance at this program is limited to healthcare professionals, and inclusion of spouses or other guests is not permitted.

Please see the most recent version of our [privacy policy](#), which may change from time to time. If you decide you no longer wish to receive communications from Sunovion, you may opt out at any time by notifying us at Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752; at 1-888-394-7377; or at [info@sunovion.com](mailto:info@sunovion.com).